Crabp2-KO Mouse

CRABP2, Cellular retinoic acid - binding protein 2, is involved in retinoid partitioning between different nuclear receptors. It is associated with multiple biological processes and signaling pathways, such as the Wnt/β - catenin, integrin/FAK/AKT, and PI3K/Akt pathways [3,4,7]. Its function is vital in various physiological and pathological conditions, and genetic models are useful for studying its role.

In cancer research, CRABP2 shows diverse effects. In melanoma, high levels of CRABP2 predict poor prognosis in patients treated with PD - 1 inhibitors, and it may regulate immunotherapy by influencing cancer - associated fibroblasts infiltration [1]. In endometrial cancer, high CRABP2 expression is linked to serous EC, reduced overall survival, advanced stage and grade [2]. In thyroid cancer, it is associated with recurrence and promotes invasion via the integrin/FAK/AKT pathway [4]. In lung cancer, it promotes metastasis via HuR and integrin β1/FAK/ERK signaling [5]. In serous ovarian cancer, it accelerates epithelial - mesenchymal transition by promoting TRIM16 methylation via upregulating EZH2 expression [6]. In prostate cancer, it promotes cell migration and invasion by activating PI3K/AKT and MAPK signalling pathways via upregulating LAMB3 [8]. In breast cancer, it functions as an oncogene promoting tumour cell proliferation, migration, and invasion [9]. In dermal papilla cells of Hu sheep, it promotes proliferation via the Wnt/β - catenin pathway [3]. In human osteoblast cells, overexpression of CRABP2 inhibits dexamethasone - induced apoptosis [7].

In conclusion, CRABP2 is involved in multiple biological processes, especially in cancer - related events such as tumorigenesis, metastasis, and immune response regulation. Research on CRABP2 using gene knockout or conditional knockout mouse models (not explicitly mentioned in the given references but generally applicable for gene function studies) could potentially further clarify its role in these disease conditions, providing insights for developing targeted therapies.